← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Crestone, Inc.
Boulder, CO
$62,481,520
Total funding
9
Grants
Funding over time
peak $15M · FY2010–25$20M$15M$10M$5M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$62,481,520 · 9
By mechanism
N01$56,422,401 · 3
R44$4,477,487 · 2
R43$1,581,632 · 4
Investigators at Crestone, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Advanced Development of Therapeutic Products for Antibiotic Resistant Bacteria$11,122,997
N01 · FY2020 · AI
Development of Therapeutic Products for Antibiotic Resistant Bacteria$9,592,833
N01 · FY2022 · AI
Development of Therapeutic Products for Biodefense, AntiMicrobial Resistant (AMR) Infections and Emerging Infectious Diseases$4,595,632
N01 · FY2024 · AI
Advanced Development of Therapeutic Products for Antibiotic Resistant Bacteria$4,519,619
N01 · FY2022 · AI
Development of Therapeutic Products for Antibacterial Resistant Infections$3,904,060
N01 · FY2025 · AI
Development of Therapeutic Products for Antibiotic Resistant Bacteria$3,717,345
N01 · FY2020 · AI
Advanced Development of Therapeutic Products for Antibiotic Resistant Bacteria$3,511,044
N01 · FY2023 · AI
Advanced Development of Medical Countermeasures for Infectious Diseases$3,439,774
N01 · FY2019 · AI
Development of Therapeutic Products for Antibiotic Resistant Bacteria$2,665,864
N01 · FY2023 · AI
Optimizing Lead Therapeutic Compounds Against Infectious Diseases$2,575,997
N01 · FY2018 · AI
Optimizing Lead Therapeutic Compounds Against Infectious Diseases$1,786,326
N01 · FY2015 · AI
Development of Therapeutic Products for Antibiotic Resistant Bacteria$1,580,854
N01 · FY2025 · AI
Optimizing Lead Therapeutic Compounds Against Infectious Diseases$1,507,181
N01 · FY2016 · AI
Development of a Novel PolC Inhibitor as a Gram-Positive Antibiotic$1,000,000
R44 · FY2012 · AI
Development of a Novel PolC Inhibitor as a Gram-Positive Antibiotic$1,000,000
R44 · FY2013 · AI
Development of a Novel PolC Inhibitor as a Gram-Positive Antibiotic$1,000,000
R44 · FY2014 · AI
Development of Therapeutic Products for Antibiotic Resistant Bacteria$970,628
N01 · FY2024 · AI
Advanced Development of Therapeutic Products for Antibiotic Resistant Bacteria$850,507
N01 · FY2021 · AI
Optimization and Lead Selection of Novel Antimycobacterial Agents$761,426
R44 · FY2015 · GM
Optimization and Lead Selection of Novel Antimycobacterial Agents$716,061
R44 · FY2016 · GM